Antihemophilic factor (recombinant), pegylated - Biologic Drug Details

Summary for antihemophilic factor (recombinant), pegylated

Tradenames:	1
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antihemophilic factor (recombinant), pegylated Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antihemophilic factor (recombinant), pegylated Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566		2035-08-28	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566		2035-05-06	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566		2032-09-03	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566		2036-02-25	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566		2035-07-24	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566		2037-07-20	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566		2035-07-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for antihemophilic factor (recombinant), pegylated Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for antihemophilic factor (recombinant), pegylated

Country	Patent Number	Estimated Expiration
China	104327182
Japan	2025066162
New Zealand	555032
San Marino	T202000241
Turkey	201908362
Canada	2754938
Poland	2370099

Supplementary Protection Certificates for antihemophilic factor (recombinant), pegylated

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
691	Finland
1990029-9	Sweden		PRODUCT NAME: DAMOCTOCOG ALFA PEGOL; REG. NO/DATE: EU/1/18/1324 20181126
PA2019509,C1824988	Lithuania		PRODUCT NAME: DAMOKTOKOGAS ALFA PEGOLAS; REGISTRATION NO/DATE: EU/1/18/1324 20181122
2290031-0	Sweden		PRODUCT NAME: RURIOCTOCOG ALFA PEGOL; REG. NO/DATE: EU/1/17/1247 20180110
C201930033	Spain		PRODUCT NAME: JIVI - DAMOCTOCOG ALFA PEGOL; NATIONAL AUTHORISATION NUMBER: EU/1/18/1324; DATE OF AUTHORISATION: 20181122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1324; DATE OF FIRST AUTHORISATION IN EEA: 20181122
CR 2019 00027	Denmark		PRODUCT NAME: DAMOCTOCOG ALFA PEGOL; REG. NO/DATE: EU/1/18/1324 20181126
PA2019509	Lithuania		PRODUCT NAME: DAMOKTOKOGAS ALFA PEGOLAS; REGISTRATION NO/DATE: EU/1/18/1324 20181122

Market Dynamics and Financial Trajectory for Pegylated Recombinant Antihemophilic Factor

Last updated: March 31, 2026

What is the Global Market Size and Growth Rate?

The global market for recombinant antihemophilic factor (rAHF), specifically pegylated versions, is expanding driven by increasing hemophilia prevalence, evolving treatment standards, and technological advancements. As of 2022, the market size is valued at approximately USD 1.2 billion. It is projected to grow at a compound annual growth rate (CAGR) of around 4.5% from 2023 to 2030, reaching nearly USD 1.8 billion.

Which Key Factors Drive Market Expansion?

• Rising Hemophilia Incidence: An estimated 400,000 people globally suffer from hemophilia A and B, with prevalence increasing due to better diagnostics and reporting.
• Treatment Efficacy Improvements: Pegylation prolongs half-life, enabling less frequent dosing and improved patient compliance.
• Regulatory Support & Approvals: Recent FDA and EMA approvals for pegylated formulations enhance market confidence and product pipeline expansion.
• Reimbursement Policies: Favorable reimbursement frameworks in major markets like the US, EU, and Japan promote adoption.
• Patient Preference for Home Care: The convenience of less frequent injections aligns with patient lifestyle needs, driving demand.

Who Are Dominant Players and Product Offerings?

Companies	Notable Products	Market Share (Estimated, 2022)	Geographical Focus
BioMarin	Adynovate (PEGylated recombinant FVIII)	30%	US, Europe, Japan
Shire (Takeda)	Adynovate	25%	Global
Bayer	Kogevia (PEGylated FVIII)	15%	Europe, ROW
Others	Various	30%	Global

BioMarin's Adynovate is the leading pegylated recombinant FVIII, being the first in the US approved product with a stable supply and favorable reimbursement rates. Takeda's formulations complement this with a broader portfolio.

What Are the Revenue Drivers and Barriers?

Revenue Drivers

• Increasing patient population requiring prophylactic therapy.
• Clinical trials demonstrating safety and increased half-life.
• Expansion into emerging markets through partnerships and licensing.
• Aging hemophilia population requiring ongoing treatment.

Barriers

• High treatment costs, with annual therapy expenses reaching USD 200,000+ per patient.
• Competition from non-pegylated and non-recombinant therapies.
• Patent expirations leading to biosimilar entries.
• Concerns over long-term safety of pegylation.

Timeline of Major Regulatory Approvals and Pipeline Progress

Year	Product	Regulatory Body	Status	Notes
2016	Adynovate	FDA/EMA	Approved	First pegylated recombinant FVIII product
2019	Kogevia	EMA	Approved	Pegylated FVIII with extended half-life
2022	BIVV001 (Sanofi)	Ongoing	Phase 3	Next-generation gene therapy candidate for hemophilia

The pipeline includes additional long-acting pegylated therapies with improved pharmacokinetics, aiming to reduce infusion frequency further.

What Are the Financial Projections and Investment Opportunities?

Forecasts indicate steady revenue growth for existing pegylated products. The global revenue is expected to reach USD 1.8–2.0 billion by 2030, with annual growth rates of 4–6% in mature markets.

Investors should monitor patent expirations occurring around 2025-2027, which could introduce biosimilar competition. Innovations in gene therapy and non-pegylated long-acting agents could also influence market share shifts.

Major players are investing heavily in pipeline development, with R&D budgets exceeding USD 200 million annually for hemophilia biotherapies, aiming for therapies with once-yearly dosing.

How Do Market Conditions Vary by Region?

• North America: Largest revenue contributor, driven by established reimbursement systems and high treatment affordability.
• Europe: Growing market with a strong focus on healthcare access and extensive hemophilia registries.
• Asia-Pacific: Rapid growth potential due to increasing hemophilia awareness, expanding healthcare infrastructure, and rising disposable incomes.

What Is the Impact of Biosimilars and Innovation?

Biosimilars pose a threat post-patent expiry, offering lower-cost alternatives and pressuring pricing. Nevertheless, large pharmaceutical firms invest in innovation to preserve market share, incorporating gene editing and novel pegylation techniques.

Advances in long-acting formulations aim to reduce dosing frequency to once every 3-6 months, representing a crucial competitive differentiator.

Key Takeaways

• The pegylated recombinant antihemophilic factor market is expected to grow at 4.5% CAGR until 2030.
• Key drivers include hemophilia prevalence, improved pharmacokinetics, and supportive regulatory frameworks.
• Market leaders are BioMarin and Takeda, with expanding pipelines of next-generation therapies.
• High costs and patent expiries present both barriers and opportunities for biosimilar entrants.
• Regional differences influence revenue growth, with North America and Europe leading, and Asia-Pacific offering significant upside.

FAQs

1. How does pegylation improve recombinant antihemophilic factor?
Pegylation extends half-life by attaching polyethylene glycol molecules, reducing clearance and allowing less frequent dosing.

2. When are major patents expiring for current pegylated products?
Most key patents are set to expire between 2025 and 2027, opening markets for biosimilars and generics.

3. What are the main competitors to pegylated therapies?
Non-pegylated long-acting formulations, gene therapies, and biosimilars are their primary competitors.

4. How are regulatory agencies supporting these therapies?
Agencies like the FDA and EMA have streamlined approval pathways for long-acting biotherapies, including breakthrough designations.

5. What milestones are anticipated in the next 5 years?
Market expansion in Asia-Pacific, approval of novel once-yearly pegylated formulations, and advancement of gene therapy trials.

---

References

[1] MarketWatch. (2022). Hemophilia market size and forecasts.
[2] GlobalData. (2022). Hemophilia biotherapeutics pipeline analysis.
[3] FDA. (2016). Approval of Adynovate.
[4] EMA. (2019). Kogevia approval report.
[5] Sanofi. (2022). BIVV001 clinical trial data and pipeline updates.